{'fraction_non_alphanumeric': 0.028532608695652172, 'fraction_numerical': 0.006793478260869565, 'mean_word_length': 5.824074074074074, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
SIRCLE: a randomised controlled cost comparison of self‐administered short‐course isoniazid and rifapentine for cost‐effective latent tuberculosis eradication

Currently, treatment of latent tuberculosis infection (LTBI) in Australia consists most commonly of a 9‐month course of isoniazid (9H). A 3‐month course of weekly isoniazid and rifapentine (3HP) has been shown to be as effective as 9 months of daily isoniazid, and associated with less hepatotoxicity; however, rifapentine is not currently available in Australia. Introduction of this regimen would have apparent advantages for people with LTBI in Victoria by safely shortening duration of LTBI therapy. However, the cost benefit of this new therapeutic approach is uncertain.